BBLG (Bone Biologics) Moat Score: 2/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBLG Bone Biologics Corp BBLG
30 GF Score
Price $1.07
View Full Analysis

What is Bone Biologics Moat Score?

Bone Biologics BBLG -0.93% 30 Moat Score is 2 as of Jul. 25, 2026. GuruFocus rates BBLG with a GF Score™ of 30/100. Among 1,396 Biotechnology companies, Bone Biologics ranks better than 58.38% on this metric.

Bone Biologics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Bone Biologics has No Moat: Bone Biologics Corp has limited market presence and lacks significant intellectual property or cost advantages. The company's competitive position is weak with no discernible moat characteristics.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bone Biologics might have No Moat - Very weak/transient advantages.

Bone Biologics  (NAS:BBLG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bone Biologics Moat Score Related Terms

BBLG vs VRAX, PKTX, OGEN: Moat Score Comparison

For the Biotechnology subindustry, Bone Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bone Biologics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bone Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where Bone Biologics's Moat Score falls into.


BBLG
30GF Score
Bone Biologics Corp BBLG
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Bone Biologics (BBLG) has a Moat Score of 2 as of Jul. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bone Biologics ranks #581 out of 1396 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Bone Biologics' Moat Score too high?
Bone Biologics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Bone Biologics' value of 2 is 0% at this industry median. Based on the distribution chart, Bone Biologics ranks #581 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' Moat Score compare to VRAX and PKTX?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #581 out of 1396 companies for Moat Score. This puts Bone Biologics in the upper half of its industry. The industry median Moat Score is 2.00. Bone Biologics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Bone Biologics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bone Biologics (BBLG), the current Moat Score is 2 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bone Biologics Business Description

Address 2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score

Get the complete analysis for BBLG

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.07
Price